Liver Diseases
Welcome,         Profile    Billing    Logout  
 306 Companies   474 Products   474 Products   223 Mechanisms of Action   25 Trials   4911 News 


«12345678910111213...9899»
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial termination, Metastases:  Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Jan 23, 2018   
    P2,  N=224, Terminated, 
    Trial primary completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Terminated
  • ||||||||||  carotuximab IV (ENV-105) / Kairos Pharma
    Trial completion, Combination therapy, IO biomarker:  Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) -  Jan 23, 2018   
    P1/2,  N=27, Completed, 
    Active, not recruiting --> Terminated Active, not recruiting --> Completed
  • ||||||||||  TheraSphere (yttrium 90 microspheres) / Boston Scientific
    Trial completion, Trial primary completion date:  MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) -  Jan 19, 2018   
    P2,  N=41, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2016
  • ||||||||||  Euvax B (recombinant hepatitis B vaccine) / LG Chem
    Trial primary completion date:  Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) -  Jan 18, 2018   
    P4,  N=132, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2016 Trial primary completion date: Dec 2017 --> Jun 2018
  • ||||||||||  ribavirin / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Ribados: Ribavirin, Its Dosing Regime (clinicaltrials.gov) -  Jan 9, 2018   
    P4,  N=15, Completed, 
    Recruiting --> Completed | Phase classification: P2 --> P2a | N=36 --> 47 | Trial primary completion date: Sep 2017 --> Feb 2017 Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Dec 2011 --> Dec 2012
  • ||||||||||  Aphthasol (amlexanox) / Abeona Therap, Esteve
    Clinical protocol, Enrollment closed:  Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=42, Active, not recruiting, 
    Trial primary completion date: Jul 2011 --> Sep 2010 Completed --> Active, not recruiting
  • ||||||||||  Trial completion, Trial primary completion date:  Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) -  Dec 12, 2017   
    P=N/A,  N=6625, Completed, 
    Completed --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2020 --> Nov 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Genetics of Fatty Liver Disease in Children (clinicaltrials.gov) -  Dec 8, 2017   
    P=N/A,  N=381, Completed, 
    Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Completed | N=1000 --> 381 | Trial primary completion date: Dec 2020 --> Jul 2017
  • ||||||||||  Enrollment change, Trial initiation date, Trial termination:  Antineoplaston Therapy in Treating Patients With Primary Liver Cancer (clinicaltrials.gov) -  Nov 21, 2017   
    P2,  N=3, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Nov 2017 N=40 --> 3 | Initiation date: Aug 1998 --> Mar 1977 | Active, not recruiting --> Terminated; Slow accrual
  • ||||||||||  pentoxifylline / Generic mfg., enoxaparin sodium / Generic mfg., ursodeoxycholic acid / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  ELDORADO: Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity (clinicaltrials.gov) -  Nov 20, 2017   
    P2,  N=22, Completed, 
    N=40 --> 3 | Initiation date: Aug 1998 --> Mar 1977 | Active, not recruiting --> Terminated; Slow accrual Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Jun 2012 --> Nov 2017
  • ||||||||||  Trial completion, Trial primary completion date:  Pediatric Liver Database (clinicaltrials.gov) -  Nov 18, 2017   
    P=N/A,  N=401, Completed, 
    Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Jun 2012 --> Nov 2017 Recruiting --> Completed | Trial primary completion date: Jun 2018 --> Sep 2016
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  HepART-RCT: Hepatitis C Alcohol Reduction Treatment (clinicaltrials.gov) -  Nov 8, 2017   
    P=N/A,  N=182, Active, not recruiting, 
    Recruiting --> Completed | N=56 --> 28 Recruiting --> Active, not recruiting | N=279 --> 182 | Trial primary completion date: Mar 2019 --> Aug 2018
  • ||||||||||  Victrelis (boceprevir) / Roche, Merck (MSD)
    Enrollment change, Trial withdrawal:  Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir. (clinicaltrials.gov) -  Nov 8, 2017   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | N=279 --> 182 | Trial primary completion date: Mar 2019 --> Aug 2018 N=60 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  rifampicin / Generic mfg.
    Trial completion, Trial primary completion date:  The Effects of PXR Activation on Hepatic Fat Content (clinicaltrials.gov) -  Nov 1, 2017   
    P4,  N=16, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017
  • ||||||||||  Phase classification, Trial initiation date, Trial primary completion date:  Dietary Intervention and Intestinal Microbiota in Non-alcoholic Fatty Liver (clinicaltrials.gov) -  Oct 26, 2017   
    P=N/A,  N=20, Completed, 
    Recruiting --> Completed Phase classification: P2 --> P=N/A | Initiation date: Jul 2011 --> Jul 2013 | Trial primary completion date: Dec 2014 --> Aug 2016
  • ||||||||||  Terlivaz (terlipressin) / Mallinckrodt
    Trial completion:  Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 (clinicaltrials.gov) -  Oct 26, 2017   
    P3,  N=112, Completed, 
    Phase classification: P2 --> P=N/A | Initiation date: Jul 2011 --> Jul 2013 | Trial primary completion date: Dec 2014 --> Aug 2016 No longer recruiting --> Completed
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Trial initiation date, Trial primary completion date:  STEN: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (clinicaltrials.gov) -  Oct 24, 2017   
    P4,  N=360, Completed, 
    No longer recruiting --> Completed Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014
  • ||||||||||  lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
    Enrollment change, Trial initiation date:  Prevention of Recurrent Hepatitis B After Liver Transplantation (clinicaltrials.gov) -  Oct 18, 2017   
    P=N/A,  N=317, Completed, 
    Recruiting --> Completed | N=150 --> 75 N=500 --> 317 | Initiation date: Jun 2001 --> Mar 2001